Skip to main content

Company

Solvonis Therapeutics PLC

LON:SVNS

Solvonis Therapeutics plc is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and proprietary discovery-stage compounds across addiction and psychiatry.

75 stories

Diversified Energy, Galliford Try, Sunda Energy, Rockfire Resources, Solvonis Therapeutics, Futura Medical - Small Cap Snapshot

By Stephen Gunnion 03/09

Solvonis Therapeutics secures key European patent for PTSD drug candidate

By Ian Lyall 03/09

Solvonis raises £1.3m to fund three clinical programmes

By Ian Lyall 25/08

US drug agency to fund further testing of Solvonis addiction candidate - UPDATE

By Ian Lyall 06/08

US Research house initiates Solvonis coverage citing differentiated addiction strategy

By Ian Lyall 13/07

Solvonis CEO on progress with potential alcohol use disorder treatment - ICYMI

By Ian Lyall 27/06

Solvonis shares up 12% after clears key hurdle in bid to treat alcohol addiction with esketamine treatment - UPDATE

By Ian Lyall 22/06

Solvonis chief scientist to address NIH addiction research forum

By Proactive 05/05

Solvonis Therapeutics results marked a successful strategic repositioning and pipeline expansion

By Proactive 02/05

Solvonis Therapeutics refines strategy around SVN-001 phase III value inflexion point

By Proactive 29/04

Solvonis Therapeutics welcomes Trump psychedelic mental health order as sector tailwind

By Proactive 20/04

Solvonis secures second US patent for PTSD drug programme within a week

By Proactive 08/04

Solvonis secures US patent for PTSD drug compounds as sector dealmaking intensifies

By Proactive 31/03

Pharma & Biotech

Solvonis PTSD drug SVN-114 targets three brain pathways - ICYMI

By Proactive 14/03

Solvonis picks lead drug candidate for PTSD programme

By Proactive 10/03

Solvonis CSO on breakthrough depression treatment and next steps - ICYMI

By Proactive 31/01

Solvonis Therapeutics expands scope of SVN-015 to potentially include depression treatment

By Proactive 28/01

Solvonis Therapeutics adds patent protection for its post-traumatic stress disorder programme

By Proactive 07/01

2025 a ‘transformative’ year as Solvonis lines up key milestones

By Proactive 22/12/2025

Solvonis jumps after US programme backs early testing of addiction drug

By Proactive 03/12/2025

Solvonis compound enters US addiction research programme backed by NIDA

By Proactive 03/12/2025

Solvonis restructures to streamline operations and focus on drug development

By Proactive 31/10/2025

Pharma & Biotech

Solvonis adds biopharma leader Paul Carter to board

By Proactive 27/10/2025

Solvonis raises £1.25m to boost CNS drug pipeline - ICYMI

By Proactive 18/10/2025

Solvonis raises £1.25 million to expand CNS drug pipeline

By Proactive 16/10/2025

Solvonis Therapeutics is advancing CNS pipeline - ICYMI

By Proactive 03/10/2025

Solvonis hails transformational first half

By Proactive 30/09/2025

Solvonis strengthens ties with Professor Nutt with exclusive CNS collaboration

By Proactive 28/08/2025

Solvonis Therapeutics: Clinical-phase innovator flies under the radar. But for how much longer?

By Proactive 15/08/2025

Solvonis Therapeutics up 13% after encouraging early-stage PTSD readout

By Proactive 12/08/2025

Solvonis enjoys early stage success as it identifies three high-performing PTSD candidates

By Proactive 12/08/2025

Solvonis begins key studies for alcohol use disorder drug ahead of US trial push

By Proactive 22/07/2025

Solvonis Therapeutics chair to speak at key industry event

By Proactive 14/07/2025

Solvonis raises £1 million from top investors to accelerate AI drug discovery

By Proactive 11/07/2025

Solvonis shares jump 10% on US patent milestone for AI-driven CNS drugs

By Proactive 23/06/2025

Solvonis moves closer to US patent for CNS drug compounds

By Proactive 23/06/2025

Solvonis Therapeutics launches AI-supported drug discovery

By Proactive 11/06/2025

Solvonis hits development milestone in PTSD drug programme

By Proactive 05/06/2025

Solvonis confirms appointment of David Nutt as chief scientist to oversee pipeline development

By Proactive 03/06/2025

Pharma & Biotech

Solvonis CEO on Awakn deal and phase III progress - ICYMI

By Proactive 31/05/2025

Solvonis Therapeutics completes acquisition of Awakn Life Sciences

By Proactive 28/05/2025

Solvonis Therapeutics raises £2m to support Awakn acquisition

By Proactive 16/05/2025

Solvonis acquisition of Awakn wins overwhelming backing from shareholders

By Proactive 23/04/2025

Solvonis chair hails ‘transformative’ 2024 as group pivots fully into mental health biotech

By Proactive 16/04/2025

Solvonis Therapeutics eyes significant commercial potential of two key assets

By Proactive 04/04/2025

Solvonis says European patent approval moves closer for trauma therapy programme

By Proactive 26/03/2025

Solvonis Therapeutics and Awakn making strides with PTSD research

By Proactive 18/03/2025

Pharma & Biotech

Solvonis Therapeutics: New non-executive director - ICYMI

By Proactive 15/03/2025

Pharma & Biotech

Solvonis hires top-tier drug developer as new non-exec director

By Proactive 11/03/2025

Solvonis Therapeutics lays out roadmap for Awakn Life Sciences acquisition

By Proactive 24/02/2025

Solvonis Therapeutics: A new player in the $450bn “neuro-psych” sector

By Proactive 07/02/2025

Pharma & Biotech

Solvonis chairman on heavy-hitting M&A in neuroscience sector - ICYMI

By Proactive 31/01/2025

Solvonis Therapeutics highlights Awakn progress on multiple fronts

By Proactive 27/01/2025

Solvonis shares surge 15% on FDA support for alcohol treatment's pathway

By Proactive 21/01/2025

Solvonis receives FDA support for clinical trial pathway

By Proactive 21/01/2025

Graft Polymer becomes Solvonis Therapeutics reflecting its focus on mental health treatments

By Proactive 14/01/2025

Pharma & Biotech

Graft Polymer CEO discusses Awakn acquisition plans - ICYMI

By Proactive 19/12/2024

Graft Polymer swoops for Awakn Life Sciences in £5m deal

By Proactive 16/12/2024

Graft Polymer unveils early encouraging results from PTSD research

By Proactive 11/12/2024

Graft Polymer reveals name-change plans; updates on collaboration

By Proactive 03/12/2024

Graft Polymer is really excited to partner with Nottingham Uni to advance mental health treatments - ICYMI

By Proactive 19/10/2024

Graft Polymer partner inks collaboration with Nottingham University researchers

By Proactive 15/10/2024

Graft Polymer partners with Eurofins to assess potential of lead asset

By Proactive 04/10/2024

Graft Polymer names Dennis Purcell as its new chair

By Proactive 26/09/2024

Graft Polymer interims chart transformation

By Proactive 13/09/2024

Graft Polymer chief executive on PTSD treatment progress - ICYMI

By Proactive 07/09/2024

Graft Polymer CEO thrilled with Awakn Life Sciences partnership progress

By Proactive 28/08/2024

Graft Polymer CFO resigns

By Proactive 12/08/2024

Graft Polymer CTO resigns and departs board

By Proactive 01/08/2024

Graft Polymer appoints Prof David Nutt as senior scientific adviser

By Proactive 30/07/2024

Graft Polymer highlights partner Awakn's patent progess

By Proactive 23/07/2024

Professor David Nutt on Awakn's PTSD drug collaboration with Graft Polymer - ICYMI

By Proactive 20/07/2024

Graft Polymer inks drug delivery collaboration with Awakn Life Sciences

By Proactive 18/07/2024

Graft Polymer notes board change

By Proactive 15/07/2024

Solvonis Therapeutics: Streamlined, sharpened and set for growth

Deep Dive - Solvonis Therapeutics PLC

By Proactive 03/02/2024